The impact of gas exchange measurement during exercise in pulmonary sarcoidosis  by Kollert, Florian et al.
Respiratory Medicine (2011) 105, 122e129ava i lab le at www.sc iencedi rect .com
journal homepage : www.e lsev ie r . com/ loca te / rmedThe impact of gas exchange measurement during
exercise in pulmonary sarcoidosisFlorian Kollert a,*, Barbara Geck b, Rolf Suchy b, Rudolf A. Jo¨rres c,
Michael Arzt a, Dominic Heidinger a, Okka W. Hamer b,d, Antje Prasse e,
Joachim Mu¨ller-Quernheim e, Michael Pfeifer a,b, Stephan Budweiser baDepartment of Internal Medicine II, Division of Pneumology, University of Regensburg, Franz-Josef-Strauss-Allee 11,
93053 Regensburg, Germany
bCenter for Pneumology, Donaustauf Hospital, Ludwigstr. 68, 93093 Donaustauf, Germany
c Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Ludwig-Maximilians-University,
Ziemssenstr. 1, 80336 Munich, Germany
d Institute of Radiology, University of Regensburg, Franz-Josef-Strauss Allee 11, 93053 Regensburg, Germany
eDepartment of Pneumology, University of Freiburg, Kilianstr. 5, 79106 Freiburg, Germany
Received 10 April 2010; accepted 4 September 2010
Available online 6 October 2010KEYWORDS
Sarcoidosis;
Gas exchange;
Exercise testing* Corresponding author. Tel.: þ49 9
E-mail address: florian.kollert@blu
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.09.007Summary
Background: Pulmonary sarcoidosis shows a remarkable heterogeneity of phenotypes ranging
from bihilar lymphadenopathy to progressive fibrosis. Individual disease assessment is
demanding and requires sensible, practical measures. We tested whether gas exchange
measurements during exercise reflects disease activity and clinical course in sarcoidosis.
Methods: In 149 patients with proven pulmonary sarcoidosis the alveolar-arterial oxygen pres-
sure gradient (P(A-a)O2) during exercise was assessed and compared with chest X-ray typing,
pulmonary function, single breath-diffusing capacity for carbon monoxide (DLCO), serological
markers, cell composition of bronchoalveolar lavage fluid (BALF) and clinical course. Patients
were categorized according to thresholds of P(A-a)O2 during exercise.
Measurements and Main Results: Chest X-ray typing, pulmonary function, DLCO and the need
for immunosuppressive treatment differed between the disease categories based on P(A-a)
O2 during exercise (p < 0.0001 each). Patients with an impairment of gas exchange during
exercise also showed elevated levels of neopterin (p Z 0.002) and higher percentages of
neutrophils (p Z 0.013) and eosinophils (p < 0.0001) in BALF. Multivariate regression analysis
showed that forced vital capacity (FVC) (pZ 0.009) and P(A-a)O2 during exercise (p < 0.0001)
were independently associated with a prolonged need for immunosuppressive treatment (>141 9447310; fax: þ49 941 9446364.
ewin.ch (F. Kollert).
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Sarcoidosis and gas exchange during exercise 123year), but not DLCO. About 50% (nZ 75) of the study population showed a normal spirometry.
Even in this subgroup 23% had an impaired gas exchange during exercise, which correlated with
chest X-ray types (p < 0.0001) and the need for immunosuppressive treatment (p < 0.005).
Conclusions: Impaired gas exchange during exercise reflects disease activity and its extent and
is associated with a prolonged need for immunosuppressive treatment during follow-up in
patients with pulmonary sarcoidosis.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a granulomatous and systemic disease with
unknown aetiology and a wide heterogeneity of disease
courses. The lung is involved in more than 90% of
patients, ranging from asymptomatic bihilar lymphade-
nopathy to progressive pulmonary fibrosis with consecu-
tive respiratory failure and premature death. The most
widely used system for categorizing the disease is chest
X-ray typing.1 It is well recognized that this categoriza-
tion does not precisely reflect clinical disease activity and
prognosis. Moreover, assignment to a certain chest X-ray
type is demanding and might vary between expert
radiologists.2
Corticosteroids are used as first line drug in sarcoidosis,
despite the fact that their long-term benefits are not
clearly proven.3 Due to variety of phenotypes and the high
potential for treatment toxicity and adverse effects, it is
crucial to identify patients with progressive disease and/or
a need for systemic medical treatment, but defining the
time point to initiate immunosuppressive treatment is
a difficult issue. The current literature recommends
systemic treatment in patients with dyspnoea and values of
forced vital capacity (FVC) or forced expiratory volume in
1 s (FEV1) <70% predicted,
4 or in case of symptomatic,
progressive disease ,4,5 while gas exchange measures are
not listed as major determinants in therapeutic decision
making.3e5 In idiopathic pulmonary fibrosis, gas exchange
measures are established as extremely valuable indices.6e8
In sarcoidosis there are also data suggesting that single
breath-diffusing capacity for carbon monoxide (DLCO) and
alveolar-arterial oxygen pressure gradient (P(A-a)O2) during
exercise might be important in estimating extent and
severity of the disease.9e14 Especially the difference of P
(A-a)O2 between exercise and rest, normalized for oxygen
uptake, has been shown to vary with chest X-ray typing.12
Thus, gas exchange during exercise could be the most
sensitive marker of disease activity, particularly in chest X-
ray types 0-II.12 However, this study comprised only a small
cohort of patients and was based on chest X-ray typing.
Thus, clinical issues and markers of disease activity were
not reported.
To our best knowledge, the thresholds for P(A-a)O2
proposed by the American Thoracic Society (ATS) and the
American College of Chest Physicians (ACCP) in a statement
on cardiopulmonary exercise testing (CPET)15 have not
been evaluated regarding their clinical usefulness in
sarcoidosis. Using these definitions the present study aimed
to assess to which extent gas exchange measurement
during exercise reflects disease activity and clinical course
in sarcoidosis.Methods
Subjects
Patientswith sarcoidosis referred to theHospital Donaustauf,
Center for Pneumology, University of Regensburg, between
12/2001 and 07/2008 were included in the present retro-
spective analysis. The diagnosis of sarcoidosis was proven by
histology or transbronchial needle aspiration (TBNA) of
enlarged hilar or mediastinal lymph nodes16 and clinical
follow-up. The decision to continue the therapy during
follow-up was made by the treating physician. Patients who
could not complete a symptom-limited CPET >6 min in the
absence of extra-cardiopulmonary limitations and patients
with clinical signs of acute infection were excluded.
Gas exchange measurements
Gas exchange at rest was assessed by the determination of
DLCO according to established standards.
17 Gas exchange
during exercise was assessed by performing CPET on an
electromagnetically braked bicycle ergometer (Ergometrics
ER900, Ergoline; Bitz, Germany) via breath-by-breath anal-
ysis using a calibrated system (Oxycon Pro, Cardinal Health
Germany 234; Ho¨chberg, Germany). Work rates in terms of
ramp increases were chosen prior to CPET according to the
individual performance state.15 Blood gases were deter-
mined from the hyperaemic earlobe at maximal exercise by
trained medical personnel. Samples were collected with
a capillary tube after incision of the earlobe and measured
with a blood gas analyzer (Rapidlab, Bayer Inc, East Wal-
pole, MA, USA). The earlobe capillary blood was arterialized
by the application of a capsicum cream (Finalgon, Boeh-
ringer-Ingelheim, Ingelheim, Germany). Arterial oxygen
tension (PaO2) is known to be underestimated in capillary
blood gas analysis compared to arterial puncture, which
represents the gold standard.18 Due to the operating
procedures of our clinic and the simple and safe procedure
in comparison to arterial catheterization, we used capillary
blood gas analysis for the estimation of PaO2. P(A-a)O2 was
calculated using the alveolar gas equation: P(A-a)
O2 Z (PiO2-PaCO2/RER)-PaO2.
15 P(A-a)O2 during exercise
normally does not exceed 20e30 mmHg in healthy individ-
uals.19,20 Following the ATS/ACCP, patients were catego-
rized into three groups: normal (P(A-a)O2 < 35 mmHg), and
moderate (35mmHg) or severe (50mmHg) impairment.15
Chest X-ray typing and pulmonary function
All patients underwent chest X-ray typing: type 0, no
abnormalities; type 1, bihilar lymphadenopathy without
124 F. Kollert et al.parenchymal abnormalities; type 2, bihilar lymphadenop-
athy with interstitial parenchymal infiltrates; type 3,
interstitial parenchymal infiltrates without bihilar lymph-
adenopathy; type 4, fibrotic changes.1 Spirometry (Mas-
terScreen, Viasys Inc.; Wu¨rzburg, Germany) followed
established standards.21
Serological markers and BALF
The levels of angiotensin converting enzyme (ACE), soluble
interleukin-2 receptor (sIL-2R) and neopterin were deter-
mined by standard procedures.22 Bronchoalveolar lavage
fluid (BALF) was obtained and processed using standard
techniques23 and evaluated for cell differentials. BALF data
were included only in patients without immunosuppressive
treatment at the time of CPET.
Follow-up
Immunosuppressive medication was documented retro-
spectively over two years after CPET from medical records
or phone interviews of patients, relatives and/or family
doctors using a standardized protocol. Only patients with
complete records of two years of retrospective follow-up
were included in this subgroup analysis (n Z 102). Written
informed consent was obtained from each subject and the
study protocol was approved by the local ethics committee.
We adhered to the Declaration of Helsinki.
Statistical analysis
Data distributions were checked on normality by the Kol-
mogoroveSmirnov-Test. All data are shown as median values
and quartiles. For the comparison of two groups the Man-
neWhitney-U-test or unpaired t-test were used for contin-
uous variables. For categorical variables the chi-square test
was used. For categorical variables with more than two
groups the ManteleHaenszel test, and for ordered variables
with more than two groups the JonckheereeTerpstra test
were used. Analysis of variance (ANOVA) was employed for
comparisons of more than two groups, either non-para-
metric KruskaleWallis or parametric ANOVA. For serological
markers, statistically significant ANOVA/KruskaleWallis
tests were followed by pair wise comparisons (Man-
neWithney-U-test). For correlation analysis Spearman rank
correlation coefficients (s) were computed. Two-sided
P-values <0.05 were considered as significant. The associ-
ation of parameters of sarcoidosis and the need for a pro-
longed immunosuppressive treatment (>1 year) were
assessed by univariate and multivariate backward binary
logistic regression analysis, with an entry level of p < 0.1
and removal level of p > 0.1. As indices for the need of
treatment we considered age (years), chest X-ray types (in
reference to type IV), DLCO (%predicted), FVC (%predicted),
P(A-a)O2 during exercise (mmHg), ACE (U/l), sIL-2R (U/ml),
neopterin (mmol/l) and the percentage of neutrophils and
eosinophils in BAL (%). Regarding to case-wise deletion
serological biomarkers were excluded for multivariate
binary logistic regression analysis. Data were collected in
a database (Microsoft Access) and analyzed by standard
statistical software (SPSS, version 16.0; Chicago, IL, USA).Results
Study population
One-hundred-forty-nine patients with sarcoidosis were
included (54 female, 36%). In 136 patients (91%) the diag-
nosis was histologically proven. In 13 patients (9%)
sarcoidosis was diagnosed by TBNA cytology and clinical
follow-up. Median (quartile) age was 47 (36; 56) years.
Patients’ characteristics according to gas exchange
thresholds for P(A-a)O2 during exercise are shown in Table
1. In 9 patients measurements of DLCO were not performed.
Chest X-ray typing, pulmonary function and DLCO
The groups categorized by ATS/ACCP thresholds for P(A-a)
O2 during exercise showed a varying distribution of,
predominantly interstitial, changes in chest X-ray typing
(p < 0.0001) and reduced FVC, FEV1 and DLCO (p < 0.0001
each) with impairment of gas exchange during exercise
(Table 1). Additionally, P(A-a)O2 during exercise correlated
with FVC (s Z 0.390, p < 0.0001), FEV1 (s Z 0.431;
p < 0.0001) and DLCO (s Z 0.621; p < 0.0001).
Serological markers and BALF
According to P(A-a)O2 during exercise thresholds, patients
with moderate (p Z 0.008) or severe (p Z 0.041) impair-
ment showed significant higher serum levels of neopterin
compared to patients with normal P(A-a)O2. There were no
statistically significant differences between these groups
regarding serum concentrations of ACE and sIL-2R (Table 1).
Analysis of BALF showed higher percentages of neutrophils
and eosinophils in patients with increased severity of gas
exchange impairment, when patients were categorized
according to P(A-a)O2 during exercise (p Z 0.013;
p < 0.0001). Regarding the percentage of lymphocytes and
the ratio of CD4- to CD8-positive lymphocytes (T4/T8) there
were no statistically significant differences (Table 1).
Follow-up
Impaired gas exchange was associated with a prolonged
immunosuppressive treatment for pulmonary sarcoidosis
during follow-up. The duration of treatment (categories: no
treatment, treatment for 1 year, treatment for >1 year)
varied significantly within the groups categorized by P(A-a)
O2 during exercise (p < 0.0001) (Table 1). In univariate
binary logistic regression analysis chest X-ray types (type I:
p Z 0.001; type II: p < 0.0001; type III: p Z 0.003, in
reference to type IV), DLCO (p < 0.0001), FVC (p < 0.0001),
P(A-a)O2 during exercise (p < 0.0001) and the percentage
of neutrophils in BAL (p Z 0.003) were associated with
a prolonged immunosuppressive treatment (>1 year),
whereas age (p Z 0.464), ACE (p Z 0.182), sIL-2R
(p Z 0.736), neopterin (p Z 0.217) and the percentage of
eosinophils in BAL (p Z 0.304) were not (Table 2).
In multivariate binary logistic regression analysis
(n Z 73) only P(A-a)O2 (p < 0.0001) and FVC (p Z 0.009)
were independently associated with a prolonged immuno-
suppressive treatment (>1 year) (Table 3).
Table 1 Patients’ characteristics according to P(A-a)O2 during exercise categories.
Variable Normal Moderate Severe p valuea
N (%) 95 (64) 36 (24) 18 (12)
Sex (F/M) 38/57 8/28 8/10 0.124
Age (years) 44 (52; 34) 49 (58; 39) 56 (62/48) 0.011
BMI (kg/m2) 27 (30; 24) 27 (30; 25) 28 (30; 26) 0.615
Hb (g/dl) 14.2 (15; 13.3) 14 (15.1; 12.9) 14.9 (15.7; 13.3) 0.302
Smoking (NS/S) 56/39 22/14 7/11 0.246
Chest X-ray (n Z 149) <0.0001
I (%) 30 (32) 0 (0) 0 (0)
II (%) 39 (41) 16 (44) 3 (17)
III (%) 25 (26) 13 (36) 4 (22)
IV (%) 1 (1) 7 (20) 11 (61)
Functional parameters
FVC (%predicted) (n Z 149) 88 (100; 81) 77 (91; 66) 61 (84; 52) <0.0001
FEV1 (%predicted) (n Z 149) 86 (98; 77) 79 (90; 52) 58 (80; 46) <0.0001
DLCO (%predicted) (n Z 140) 83 (92; 76) 67 (77; 53) 42 (59; 32) <0.0001
Serological markers (n Z 77)
ACE (U/l) 49 (74; 38) 66 (104; 37) 72 (115; 17) 0.458
sIL-2R (U/ml) 927 (1422; 704) 1359 (1927; 770) 1132 (1689; 535) 0.272
Neopterin (mmol/l) 11 (15; 8) 24 (36; 19)* 16 (26; 10)** 0.002
BALF differentials (n Z 111)
Lymphocytes (%) 27.1 (39.9; 13.9) 36.8 (46.2; 13.0) 24.3 (62.4; 10.1) 0.601
T4/T8 2.8 (5.4; 1.4) 4.3 (7.1; 1.7) 3.1 (5.6; 1.9) 0.590
Neutrophiles (%) 0.8 (1.6; 0.3) 1.8 (3.7; 0.5) 7.9 (13.2; 0.4) 0.013
Eosinophiles (%) 0.0 (0.2; 0.0) 0.0 (0.6; 0.0) 0.5 (1.6; 0.2) <0.0001
Systemic Treatment (n Z 102) <0.0001
None 33 (56) 3 (11) 0 (0)
1 year 18 (30) 11 (41) 2 (12)
>1 year 8 (14) 13 (48) 14 (88)
Data are shown as number of patients with the respective percentage, or as median values (quartiles in parentheses) within the
categories defined by the thresholds of P(A-a)O2 during exercise according to ATS/ACCP: normal (<35 mmHg), and moderate
(35 mmHg) or severe (50 mmHg) impairment
Definitions of abbreviations: P(A-a)O2Z alveolar-arterial oxygen pressure gradient during exercise; FZ female; MZ male; BMIZ body
mass-index; Hb Z haemoglobin; NS Z never or former smokers; S Z current smokers; FVC Z forced vital capacity; FEV1 Z forced
expiratory volume in 1 s; DLCO Z single breath-diffusing capacity for carbon monoxide; ACE Z Angiotensin converting enzyme; sIL-
2R Z soluble Interleukin-2 receptor; BALF Z bronchoalveolar lavage fluid; T4/T8 Z ratio of CD4- to CD8-positive cells.
a Test on a statistical difference between the three groups, using either KruskaleWallis, parametric one-way ANOVA, chi-square
testing, ManteleHaenszel’s statistic or JonckheereeTerpstra test. For serological biomarkers ANOVA was followed by pair wise testing
(ManneWithney-U-Test) in case of significance. Patients with moderate (*p Z 0.008), or severe (**p Z 0.041) impairment showed
higher serum concentrations of neopterin in comparison to patients with normal diffusing capacity. Only 6 patients were treated with
azathioprine (all patients with treatment duration of >1 year), otherwise immunopressive treatment was a monotherapy with
corticosteroids.
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Seventy-five patients (50%) showed a normal spirometry
definedbyFEV1 andFVC80%predicted.Of thesepatients, 26
(35%) were categorized as chest X-ray type I, 27 (36%) as type
II, and 22 (29%) as type III. Theirmedian (quartiles) agewas 47
(35; 56) years. Seventeen patients (23%) of this subpopulation
showed an impaired gas exchange during exercise according
to P(A-a)O2 thresholds (normal, n Z 58 (77%); moderate,
nZ 14 (19%); severe impairment, nZ 3 (4%)).
P(A-a)O2 during exercise differed between chest X-ray
types (p < 0.0001) and increased with the need for immu-
nosuppressive treatment even in patients with normal
spirometry (p < 0.005) (Fig. 1). Patients with no need fortreatment showed P(A-a)O2 values of 28 (23; 32) mmHg,
patients with treatment for 1 year 37 (31; 47) mmHg, and
patients with treatment for >1 year 39 (28; 63) mmHg.
Discussion
This study shows that gas exchange limitation during
exercise reflects the degree of functional impairment,
disease extent, inflammatory activity and the need for
systemic treatment in patients with pulmonary sarcoidosis.
Moreover, multivariate regression analysis revealed that
FVC and P(A-a)O2 during exercise were independently
associated with a prolonged need for immunosuppressive
treatment, whereas DLCO was not. Even in patients with
Table 2 Need for prolonged immunosuppressive therapy (>1 year) according to univariate binary logistic regression analyses
performed for each predictor separately.
Independent variable Odds ratio (95% CI) p value
Age (years) 0.988 (0.957 e 1.020) 0.464
Chest X-ray type Ia 0.016 (0.002 e 0.0179) 0.001
Chest X-ray type IIa 0.067 (0.016 e 0.281) <0.0001
Chest X-ray type IIIa 0.113 (0.026 e 0.487) 0.003
DLCO (%predicted) 0.951 (0.925 e 0.977) <0.0001
FVC (%predicted) 0.936 (0.909 e 0.965) <0.0001
P(A-a)O2 during exercise (mmHg) 1.113 (1.062 e 1.167) <0.0001
ACE (U/l) 1.010 (0.996e1.024) 0.182
sIL-2R (U/ml) 1.000 (0.999 e 1.001) 0.736
Neopterin (mmol/l) 1.035 (0.980e1.093) 0.217
Neutrophiles in BAL (%) 1.357 (1.109 e 1.660) 0.003
Eosinophiles in BAL (%) 1.531 (0.680 e 3.447) 0.304
Definitions of abbreviations: P(A-a)O2 Z alveolar-arterial oxygen pressure gradient during exercise; FVC Z forced vital capacity;
DLCO Z single breath-diffusing capacity for carbon monoxide; CI Z confidence interval.
a Chest X-ray type IV was used as reference. Besides chest X-ray types all parameter were analysed as continuous variables.
126 F. Kollert et al.values of FVC and FEV1 in the normal range, a significant
proportion showed evidence for an impaired gas exchange
during exercise, associated with predominantly interstitial
changes in chest X-ray typing and prolonged treatment
during follow-up. Based on these findings we consider gas
exchange measurement during exercise as suitable to
become an integral part of assessment and monitoring in
pulmonary sarcoidosis.
Medinger and co-workers already suggested P(A-a)O2
during exercise to be a sensitive measure of the extent of
pulmonary sarcoidosis.12 To our best knowledge, the P(A-a)
O2 thresholds proposed by the ATS/ACCP statement, which
we used, have not been evaluated in detail in sarcoidosis.15
Based on a population of 149 patients with sarcoidosis, we
found that these thresholds corresponded to the disease
characteristics derived from chest X-ray typing. Moreover,
they appeared to be of functional significance, being
associated with the values of FVC, FEV1 and DLCO.
Regarding serological markers and BALF differentials, we
observed that P(A-a)O2 during exercise according to
ATS/ACCP thresholds reflected inflammatory disease
activity. Compared to patients with normal P(A-a)O2, neo-
pterin serum levels were gradually elevated in those with
moderate or severe impairment. This is of interest, as
neopterin indicates activation of the monocyte/macro-
phage system, an important player in the pathogenesis of
sarcoidosis.24 Activated macrophages contribute to the
development of pulmonary fibrosis.25,26 Thus neopterin




P(A-a)O2 during exercise (mmHg)
Besides chest X-ray types all parameter were analysed as continuous
Definitions of abbreviations: P(A-a)O2 Z alveolar-arterial oxygen p
CI Z confidence interval.translated into abnormalities of gas exchange. In contrast
to neopterin, sIL2-R levels were not significant increased
with gas exchange impairment. sIL-2R, as a marker of T-cell
activation, is associated with a better prognosis and
a normalization of chest X-ray findings in sarcoidosis.27
However, sIL2-R has its most prominent role in acute
sarcoidosis which often shows extrapulmonary domi-
nance.22,27 Serum levels of ACE are known to be elevated in
only about 60% of patients with sarcoidosis,4 and there is
growing evidence that ACE does not well reflect disease
activity.22,28,29 In accordance with this, ACE did not signif-
icantly vary with gas exchange impairment in our study.
Patients with gas exchange impairment during exercise
also showed higher percentages of neutrophils and eosino-
phils in BALF. Neutrophil numbers in BALF might be asso-
ciated with the severity and course of the disease,30 and
high percentages of neutrophils (>3%) and eosinophils
(>1%) have been reported to indicate a greater likelihood
for the necessity of immunosuppressive treatment, and
probably also for disease progression.23 Our results are in
line with this, as they demonstrated an increase in the
proportions of both cell types with increasing severity of
gas exchange impairment.
We also analyzed the predictive value of gas exchange
measures regarding the need for immunosuppressive
therapy. The role of P(A-a)O2 for treatment decision in
pulmonary sarcoidosis has so far not been evaluated. Our
data showed a prolonged need for immunosuppressive
treatment in patients with impaired gas exchange accordingyear) according to multivariate backward binary logistic




ressure gradient during exercise; FVC Z forced vital capacity;
Figure 1 Alveolar-arterial oxygen pressure gradient (P(A-a)O2) during exercise in patients with sarcoidosis and normal spirom-
etry, defined by forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) 80%predicted, categorized by chest X-ray
typing (type I, n Z 26; type II, n Z 27; type III, n Z 22) and the need for immunosuppressive treatment (no treatment, n Z 27;
treatment for 1 year, n Z 12; treatment for >1 year, n Z 6). Comparisons between the groups were based on KruskaleWallis
testing. P(A-a)O2 during exercise was increasing with chest X-ray types (***p < 0.0001) and the need for immunosuppressive
treatment (**p < 0.005).
Sarcoidosis and gas exchange during exercise 127to P(A-a)O2 thresholds as proposed by ATS/ACCP. In multi-
variate regression analysis we could show that P(A-a)O2
during exercise (as continuous variable) is superior to DLCO
in predicting the need for long-term immunosuppressive
treatment These are the first data indicating a prognostic
value of P(A-a)O2 during exercise in pulmonary sarcoidosis.
It has been reported that immediate treatment was
associated with improved pulmonary function over 5 years
of follow-up especially in patients with chest X-ray type
II.31 The present study showed that gas exchange impair-
ment during exercise occurred frequently and was associ-
ated with interstitial changes in chest X-ray typing even in
patients with normal spirometry. This again is fully in line
with other data. For example, Judson and co-workers
already showed that FEV1 and FVC not always change in
parallel to chest X-ray typing in sarcoidosis.32 As we found
that prolonged immunosuppressive treatment in patients
with normal spirometry corresponded to impairments of gas
exchange prior to therapy, P(A-a)O2 during exercise might
be useful for detecting early, not easily detectable paren-
chymal involvement, as an indicator of the need for
systemic therapy.
In addition to P(A-a)O2, FVC was independently associ-
ated with a prolonged immunosuppressive treatment in
follow-up, whereas DLCO was not. DLCO is known as
a sensitive parameter, which is often impaired even in
patients with normal spirometry.33 However, there are also
data indicating that DLCO might be normal in sarcoidosis
patients with known restrictive ventilatory impairment.6
On one hand, these conflicting results appear to illus-
trate the heterogeneity of functional impairments in
sarcoidosis. The higher average predictive value of FVC for
a prolonged immunosuppressive treatment underlines the
importance of a multi-parametric disease assessment. It is
also important to note that DLCO mainly assesses pulmo-
nary capillary blood volume, and only to a lesser extent
proper diffusing impairments which are to be best assessed
by NO diffusing capacity.34 On the other hand, it is well
possible structural that alterations that affect gas
conductivity are reflected in volume changes of the lungand particularly become manifest under stress conditions
for gas uptake as imposed by exercise. We thus believe
that the predictive value of single measures and their
ranking depends on the patient population studied. This is
why we advocate a multi-dimensional approach and would
not consider it wise to rely upon a single measure. None-
theless, our data show that P(A-a)O2 represents one of the
measures that should be included in this panel. Restrictive
ventilatory failure in patients with sarcoidosis also reflects
respiratory muscle weakness and fatigue35 and thus might
additionally indicate a systemic component of disease,
which probably also favours FVC in predicting a prolonged
treatment in pulmonary sarcoidosis. Moreover, smoking
can confounds the measurement of DLCO, although not to
a large extent. In our patient cohort there was a high
heterogeneity in smoking behaviour which could have
influenced our findings. Finally, the high correlation of
DLCO and P(A-a)O2 probably could also affect the ranking in
multivariate regression analysis regarding the superiority
of FVC in comparison to DLCO.
This investigation naturally has limitations. Comprising
a large number of patients, data were collected over a long
period of time, without strict adherence to a standardized
study protocol or regular follow-up visits. Moreover, initial
therapeutic decisions were made while being aware of the
values of P(A-a)O2 during exercise. However, the treatment
over 2 years was performed in an outpatient setting without
re-evaluation in our hospital. Moreover, the magnitude of P
(A-a)O2 during exercise is related to age. This could not be
considered in our study, as reliable, individual normal
values are lacking. Such values could further improve the
value of gas exchange measurement during exercise.
Capillary blood gas analysis is known to underestimate
arterial PaO2.
18 To minimise this bias, blood gas analysis
was performed by trained personnel, who specifically was
aware of an adequate arterialization of the earlobe.
Nevertheless the values of P(A-a)O2 might be false high in
our study.
In conclusion, our study highlights the clinical value of
gas exchange measurement during exercise in sarcoidosis
128 F. Kollert et al.with pulmonary involvement. Disease activity, extent and
clinical course were reflected by the thresholds for P(A-a)
O2 during exercise as proposed by the ATS/ACCP. These
categories are easily applicable in clinical routine and
might also be useful for testing the efficacy of novel ther-
apeutic approaches. Moreover gas exchange impairment
during exercise was associated with a prolonged need for
immunosuppressive treatment. Whether this is of prog-
nostic value in sarcoidosis has to be investigated in future
prospective studies.
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